Markets:

Overview

News

Currencies

International

Treasuries

Theravance Biopharma, Inc. - Ordinary Shares (NQ:TBPH)

16.57 -0.07 (-0.42%)

Streaming Delayed Price Updated: 10:17 AM EDT, Apr 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Theravance Biopharma, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

October 16, 2025

From Theravance Biopharma

Via Business Wire

This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗

September 12, 2025

Via Benzinga

Theravance Sales Jump 83 Percent ↗

August 12, 2025

Via The Motley Fool

Theravance Biopharma Inc (NASDAQ:TBPH) Misses Q2 2025 Revenue and EPS Estimates Amid Mixed Market Reaction ↗

August 12, 2025

Theravance Biopharma (TBPH) Q2 2025 earnings missed revenue and EPS estimates, but stock rose 3.1% after-hours. Focus remains on YUPELRI and Ampreloxetine pipeline.

Via Chartmill

Topics Earnings

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Unveiling 4 Analyst Insights On Theravance Biopharma ↗

September 16, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Theravance Biopharma ↗

August 06, 2024

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

June 17, 2025

Via Benzinga

TBPH Stock Earnings: Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024 ↗

August 05, 2024

TBPH stock results show that Theravance Biopharma beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Via InvestorPlace

Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

June 12, 2024

Via Benzinga

Sidoti Events, LLC's Virtual June Small-Cap Conference

June 11, 2024

Via ACCESSWIRE

Recap: Theravance Biopharma Q4 Earnings ↗

February 26, 2024

Via Benzinga

A Preview Of Theravance Biopharma's Earnings ↗

February 23, 2024

Via Benzinga

TBPH Stock Earnings: Theravance Biopharma Beats EPS, Beats Revenue for Q1 2024 ↗

May 13, 2024

TBPH stock results show that Theravance Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

BTIG Research Predicts Over 118% Rally for These 3 Stocks ↗

April 15, 2024

Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.

Via InvestorPlace

Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics ↗

March 12, 2024

Although the bears see cynical opportunities, you can make give them a taste of their own medicine with these short-squeeze stocks.

Via InvestorPlace

Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

January 23, 2024

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday.

Via Benzinga

Topics Stocks

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

January 05, 2024

Shares of Applied Therapeutics, Inc.

Via Benzinga

Earnings Scheduled For February 26, 2024 ↗

February 26, 2024

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.

Via Benzinga

Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today? ↗

January 05, 2024

Theravance Biopharma Inc (NASDAQ: TBPH) announced results from the Phase 4 PIFR-2 study of Yupelri (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 05, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

January 05, 2024

Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning!

Via InvestorPlace

Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 05, 2024

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.

Via Benzinga

Topics Stocks

7 Short-Squeeze Stocks That Are Screaming for Speculation ↗

December 24, 2023

If you like to march to your own beat even against high pressure, these short-squeeze stocks could be right for you.

Via InvestorPlace

Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗

November 18, 2023

Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...

Via Talk Markets

Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday ↗

November 08, 2023

U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Earnings Scheduled For November 7, 2023 ↗

November 07, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.